RxDoctor Payments Data

Eric Klappholz

Adult Health · Dallas, TXNPI 1003258856

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Viiv Healthcare Company accounts for 74.4% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $23,784, more than ten times the $2,285 reported in 2021. Among adult health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$43,721in general payments, 2019–2025

Across 566 payments — averaging $77.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$33K
  • Gilead$6K
  • Merck$1K
  • Novo Nordisk$698
  • EMD Serono, Inc.$470
  • Lilly USA, LLC$433
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$2,1805%
  • Speaking & faculty fees$23,25053%
  • Travel & lodging$4,56210%
  • Food & beverage$13,55831%
  • Education$1710%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,721 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala44$207,969
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf15$79,725
DovatoDolutegravir Sodium/Lamivudine19$52,668
DescovyEmtricitabine/Tenofov Alafenam19$47,085
TivicayDolutegravir Sodium17$43,826
OzempicSemaglutide28$30,592
Atorvastatin Calcium24$286
Acyclovir13$278
Lisinopril17$111
Losartan Potassium14$57
Amlodipine Besylate11$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$6,214$255,05463 claims
Viiv Healthcare CompanyDovato, Tivicay$32,528$96,49436 claims
Janssen Products, LPSymtuza$149$79,72515 claims
Novo NordiskOzempic$698$30,59228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.

Other adult health in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →